Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Matthew Civitello, Annemarie Rohwer, Francesca Salmin, Allan M. Glanzman, Jacqueline Montes, Amy Pasternak, Roberto De Sanctis, Sally Dunaway Young, Tina Duong, Irene Mizzoni, Evelin Milev, Maria Sframeli, Simone Morando, Emilio Albamonte, Adele D'Amico, Michela Catteruccia, Noemi Brolatti, Marika Pane, Mariacristina Scoto, Sonia Messina, Jesica Exposito Escudero, Liesbeth De Waele, Michio Hirano, Zarazuela Zolkipli-Cunningham, Basil T. Darras, Enrico Bertini, Andres Nascimiento Osorio, Claudio Bruno, Natalie Goemans, Valeria A. Sansone, John Day, Giovanni Baranello, Francesco Muntoni, Richard Finkel, Eugenio Mercuri, the ISMAC/international SMA consortium
{"title":"II 型和 III 型脊髓性肌萎缩症的长期自然史:一项为期 4 年的哈默史密斯功能性运动量表扩展国际研究。","authors":"Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Matthew Civitello, Annemarie Rohwer, Francesca Salmin, Allan M. Glanzman, Jacqueline Montes, Amy Pasternak, Roberto De Sanctis, Sally Dunaway Young, Tina Duong, Irene Mizzoni, Evelin Milev, Maria Sframeli, Simone Morando, Emilio Albamonte, Adele D'Amico, Michela Catteruccia, Noemi Brolatti, Marika Pane, Mariacristina Scoto, Sonia Messina, Jesica Exposito Escudero, Liesbeth De Waele, Michio Hirano, Zarazuela Zolkipli-Cunningham, Basil T. Darras, Enrico Bertini, Andres Nascimiento Osorio, Claudio Bruno, Natalie Goemans, Valeria A. Sansone, John Day, Giovanni Baranello, Francesco Muntoni, Richard Finkel, Eugenio Mercuri, the ISMAC/international SMA consortium","doi":"10.1111/ene.16517","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and purpose</h3>\n \n <p>Spinal muscular atrophy (SMA) is a genetic disorder caused by <i>SMN1</i> gene mutations. Although studies on available disease-modifying treatments have reported their efficacy and safety, long-term natural history data are lacking for comparison. The aim of this prospective study was to report 4-year changes on the Hammersmith Functional Motor Scale Expanded (HFMSE) in type II and III SMA in relation to several variables such as age, functional status and <i>SMN2</i> copy number.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study involves retrospective analysis of prospectively collected data from international datasets (Belgium, Italy, Spain, USA, UK). HFMSE longitudinal changes were analyzed using linear mixed effect models, examining annualized HFMSE change and its association with variables such as age at baseline, sex, motor function, <i>SMN2</i> copy number.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In SMA type II (<i>n</i> = 226), the 4-year mean change was −2.20 points. The largest mean changes were observed in sitters aged 5–14 years and the lowest in those who lost the ability to sit unsupported. In SMA type III (<i>n</i> = 162), the 4-year mean change was −2.75 points. The largest mean changes were in those aged 7–15 years, whilst the lowest were in those below 7 and in the SMA type IIIa subgroup over 15. Age and score at baseline were predictive of 4-year changes.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our findings provide natural history reference data for comparison with long-term follow-up of clinical trials or real-world data, highlighting the need to define patterns of changes in smaller SMA subgroups instead of reporting mean changes across an entire SMA cohort.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555017/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded\",\"authors\":\"Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, Matthew Civitello, Annemarie Rohwer, Francesca Salmin, Allan M. Glanzman, Jacqueline Montes, Amy Pasternak, Roberto De Sanctis, Sally Dunaway Young, Tina Duong, Irene Mizzoni, Evelin Milev, Maria Sframeli, Simone Morando, Emilio Albamonte, Adele D'Amico, Michela Catteruccia, Noemi Brolatti, Marika Pane, Mariacristina Scoto, Sonia Messina, Jesica Exposito Escudero, Liesbeth De Waele, Michio Hirano, Zarazuela Zolkipli-Cunningham, Basil T. Darras, Enrico Bertini, Andres Nascimiento Osorio, Claudio Bruno, Natalie Goemans, Valeria A. Sansone, John Day, Giovanni Baranello, Francesco Muntoni, Richard Finkel, Eugenio Mercuri, the ISMAC/international SMA consortium\",\"doi\":\"10.1111/ene.16517\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and purpose</h3>\\n \\n <p>Spinal muscular atrophy (SMA) is a genetic disorder caused by <i>SMN1</i> gene mutations. Although studies on available disease-modifying treatments have reported their efficacy and safety, long-term natural history data are lacking for comparison. The aim of this prospective study was to report 4-year changes on the Hammersmith Functional Motor Scale Expanded (HFMSE) in type II and III SMA in relation to several variables such as age, functional status and <i>SMN2</i> copy number.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The study involves retrospective analysis of prospectively collected data from international datasets (Belgium, Italy, Spain, USA, UK). HFMSE longitudinal changes were analyzed using linear mixed effect models, examining annualized HFMSE change and its association with variables such as age at baseline, sex, motor function, <i>SMN2</i> copy number.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In SMA type II (<i>n</i> = 226), the 4-year mean change was −2.20 points. The largest mean changes were observed in sitters aged 5–14 years and the lowest in those who lost the ability to sit unsupported. In SMA type III (<i>n</i> = 162), the 4-year mean change was −2.75 points. The largest mean changes were in those aged 7–15 years, whilst the lowest were in those below 7 and in the SMA type IIIa subgroup over 15. Age and score at baseline were predictive of 4-year changes.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Our findings provide natural history reference data for comparison with long-term follow-up of clinical trials or real-world data, highlighting the need to define patterns of changes in smaller SMA subgroups instead of reporting mean changes across an entire SMA cohort.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11954,\"journal\":{\"name\":\"European Journal of Neurology\",\"volume\":\"31 12\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555017/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ene.16517\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.16517","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:脊髓性肌萎缩症(SMA)是一种由 SMN1 基因突变引起的遗传性疾病。尽管对现有疾病改变疗法的研究报告了其疗效和安全性,但缺乏长期自然病史数据进行比较。这项前瞻性研究的目的是报告 II 型和 III 型 SMA 患者哈默史密斯功能运动量表(HFMSE)4 年来的变化与年龄、功能状态和 SMN2 拷贝数等变量的关系:该研究对从国际数据集(比利时、意大利、西班牙、美国、英国)中收集的前瞻性数据进行了回顾性分析。采用线性混合效应模型分析HFMSE的纵向变化,研究HFMSE的年化变化及其与基线年龄、性别、运动功能、SMN2拷贝数等变量的关系:在SMA II型患者(n = 226)中,4年的平均变化为-2.20分。5-14岁坐位者的平均变化最大,失去无支撑坐位能力者的平均变化最小。在 SMA III 型(n = 162)中,4 年的平均变化为-2.75 分。平均变化最大的是 7-15 岁的儿童,最小的是 7 岁以下的儿童和 15 岁以上的 SMA IIIa 型亚组。年龄和基线得分可预测4年的变化:我们的研究结果提供了自然史参考数据,可与临床试验的长期随访或真实世界的数据进行比较,同时强调有必要确定较小 SMA 亚组的变化模式,而不是报告整个 SMA 队列的平均变化。
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded
Background and purpose
Spinal muscular atrophy (SMA) is a genetic disorder caused by SMN1 gene mutations. Although studies on available disease-modifying treatments have reported their efficacy and safety, long-term natural history data are lacking for comparison. The aim of this prospective study was to report 4-year changes on the Hammersmith Functional Motor Scale Expanded (HFMSE) in type II and III SMA in relation to several variables such as age, functional status and SMN2 copy number.
Methods
The study involves retrospective analysis of prospectively collected data from international datasets (Belgium, Italy, Spain, USA, UK). HFMSE longitudinal changes were analyzed using linear mixed effect models, examining annualized HFMSE change and its association with variables such as age at baseline, sex, motor function, SMN2 copy number.
Results
In SMA type II (n = 226), the 4-year mean change was −2.20 points. The largest mean changes were observed in sitters aged 5–14 years and the lowest in those who lost the ability to sit unsupported. In SMA type III (n = 162), the 4-year mean change was −2.75 points. The largest mean changes were in those aged 7–15 years, whilst the lowest were in those below 7 and in the SMA type IIIa subgroup over 15. Age and score at baseline were predictive of 4-year changes.
Conclusions
Our findings provide natural history reference data for comparison with long-term follow-up of clinical trials or real-world data, highlighting the need to define patterns of changes in smaller SMA subgroups instead of reporting mean changes across an entire SMA cohort.
期刊介绍:
The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).